ClinicalTrials.gg
CompletedNCT01210495Updated Jan 9, 2019Results posted

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

A Phase 2 interventional study of Axitinib (AG-013736) and Best Supportive Care in Hepatocellular Carcinoma, sponsored by Pfizer. Completed at 77 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-09.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Carcinoma, Hepatocellular by Pfizer — 2 open to participants now, 2 under way, none of them phase 3. Carcinoma, Hepatocellular · Pfizer.

Enrollment
3rd of 12
224 · median 113
Started
2010
the only one that year
Phase 2
3 of 12
none open now
Registered
4th of 12
by date

Among the 12 studies in Carcinoma, Hepatocellular by Pfizer, this one is the 3rd largest by enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 4th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

2 of the 12 studies in Carcinoma, Hepatocellular by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Carcinoma, Hepatocellular by Pfizer, or all of them as a file.
02

Study summary

The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced or HCC
  • Failure of one prior antiangiogenic therapy including sorafenib, bevacizumab and brivanib.
  • Class A or B (score 7 only) disease.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment of advanced HCC with more than one prior systemic therapy.
  • Any prior local therapy within 2 weeks of starting the study treatment.
  • Presence of hepatic encephalopathy and/or ascites.
  • Presence of main portal vein invasion by HCC.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    A

    Participants in this group received axitinib + best supportive care. Participants with Child-Pugh Class A disease (score 5 or 6) were enrolled into the randomized portion at a starting axitinib dose of 5 mg BID orally. Participants with Child-Pugh Class B disease (score 7) were to begin enrollment into the randomized portion of the study following determination of the recommended axitinib starting dose in the non-randomized portion. Study treatment was administered in cycles of 4 weeks in duration

    Drug: Axitinib (AG-013736) · Other: Best Supportive Care

  • Placebo comparator
    B

    Participants in this group received placebo + best supportive care. Treatment was administered in cycles of 4 weeks in duration. The starting dose of placebo for participants with Child Pugh Class A disease (score 5 or 6) was chosen as 5 mg BID. Participants with Child-Pugh Class B, score 7 received placebo that was determined from the non-randomized portion of the study until the recommended starting dose was determined, participants with Child-Pugh Class B, score 7, were not permitted to enter the randomized portion of the study

    Drug: Placebo · Other: Best Supportive Care

Interventions

  • Axitinib \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID

  • OtherBest Supportive Care

    BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.

  • DrugPlacebo

    Placebo \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID

  • OtherBest Supportive Care

    BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) - Stratified Analysis, Randomized Portion

    OS was defined as the time from the date of randomization to the date of death due to any cause. OS (in months) was calculated as (date of death - first randomization date +1)/30.4. For participants still alive at the time of the analysis, the OS time was censored on the last date they were known to be alive. All participants were followed up for survival at least every 3 months after discontinuing study treatment until at least two years after randomization of the last participant.

    Time frame: From randomization until at least two years after the last participant has been randomized (up to 6 years)

Secondary outcomes

  1. Progression-Free Survival (PFS) - Stratified Analysis, Randomized Portion

    PFS was defined as time from randomization to first documented objective tumor progression or to death due to any cause, whichever occurred first. PFS (in months) was calculated as (first event date - first randomization date +1)/30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was death). As per response evaluation criteria in solid tumors (RECIST) 1.1, progression was defined as greater than or equal to (\>=) 20% increase in sum of longest dimensions of target lesions or appearance of one or more new target lesions and unequivocal progression of existing non-target lesions, or appearance of 1 new non-target lesions. Participants discontinuing study treatment without documented evidence of PD were to be followed up at least every 8 weeks after discontinuing study treatment until disease progression, or initiation of another anticancer treatment.

    Time frame: Every 8 weeks until disease progression/death or start of new treatment or until at least two years after the last participant has been randomized, whatever occurs first

  2. Objective Response Rate (ORR) - Percentage of Participants With Objective Response by Stratified Analysis, Randomized Portion

    ORR was defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) according to the RECIST 1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must decrease to normal (short axis \<10 millimetres \[mm\]). PR was defined as a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: Every 8 weeks until at least two years after the last participant has been randomized

  3. Time to Tumor Progression (TTP) - Stratified Analysis, Randomized Portion

    TTP was defined as the time from randomization to first documentation of objective tumor progression. If tumor progression data included more than 1 date, the first date was used. TTP (in months) was calculated as (first event date - first randomization date +1)/30.4.

    Time frame: Every 8 weeks until disease progression/death or start of new treatment or until at least two years after the last participant has been randomized, whatever occurs first

  4. Duration of Response (DR) by Unstratified Analysis, Randomized Portion

    DR was defined as the time from the first documentation of objective tumor response (CR or PR) that was subsequently confirmed to the first documentation of PD or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date was to be used. DR (in months) was to be calculated as (the end date for DR - first CR or PR that was subsequently confirmed +1)/30.4.

    Time frame: From objective response to date of progression or death

  5. Percentage of Participants With Overall Clinical Benefit Response (CBR) - Stratified Analysis, Randomized Portion

    CBR was defined as the percentage of participants with confirmed CR or confirmed PR or a best response of stable disease \>=8 weeks according to RECIST 1.1 criteria, relative to all randomized participants who had baseline measurable disease. Confirmed responses were defined as those that persisted on repeat imaging study \>=4 weeks after the initial documentation of response. Participants who did not have on study radiographic tumor re-evaluation or who died, progressed, or dropped out for any reason prior to reaching a CR, PR, or stable disease were counted as non-responders in the assessment of CBR. A participant who initially met the criteria for a PR and then subsequently became a confirmed CR was to be assigned a best response of CR.

    Time frame: From Baseline up to end of treatment

  6. Axitinib Steady-State Pharmacokinetic (PK) Parameter - Maximum Observed Plasma Concentration (Cmax), Non-Randomized Portion

    Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing.

    Time frame: Cycle 1 Day 15

  7. Axitinib Steady-State PK Parameter - Area Under the Plasma Concentration Versus Time Curve From 0 to 24 Hour (AUC0-24), Non-Randomized Portion

    Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.

    Time frame: Cycle 1 Day 15

  8. Axitinib Steady-State Pharmacokinetic Parameter - Time to First Occurrence of Cmax (Tmax), Non-Randomized Portion

    Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing.

    Time frame: Cycle 1 Day 15

  9. Axitinib Steady-State Pharmacokinetic Parameter - Apparent Oral Clearance (CL/F), Non-Randomized Portion

    Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.

    Time frame: Cycle 1 Day 15

  10. Axitinib Steady-State Pharmacokinetic Parameter - Terminal Plasma Elimination Half-Life (t1/2), Non-Randomized Portion

    Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.

    Time frame: Cycle 1 Day 15

  11. Axitinib Steady-State Pharmacokinetic Parameter - Apparent Oral Volume of Distribution of the Drug During the Elimination Phase (Vz/F), Non-Randomized Portion

    Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. The PK parameter, Vz/F has been presented in this outcome measure. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.

    Time frame: Cycle 1 Day 15

  12. Concentration of Soluble Proteins at Baseline in Randomized Portion

    Plasma soluble proteins interleukin-6 (IL-6), E-Selectin, interleukin-8 (IL-8), hepatocyte growth factor (HGF), matrix metalloproteinase-2 (MMP-2), stem cell factor (SCF), angiopoietin-2 (Ang-2), vascular endothelial growth factor-A (VEGF-A), vascular endothelial growth factor-C (VEGF-C), soluble vascular endothelial growth factor receptor 2 (sVEGFR2), soluble vascular endothelial growth factor receptor 3 (sVEGFR3), stromal cell-derived factor-1 (SDF1), neutrophil gelatinase-associated lipocalin (NGAL), migration inhibitory factor (MIF), c-MET, regulated upon activation normal T cell expressed and presumably secreted (RANTES), and monocyte chemotactic protein-3 (MCP-3) were only measured in randomized participants.

    Time frame: Baseline

  13. Percentage of Participants With Specific Micro-Ribonucleic Acid (miRNA) Transcript Present in Circulation in Randomized Portion

    A 5 millilitres (mL) whole blood sample was collected from all randomized participants to evaluate the miRNA transcripts.

    Time frame: Baseline

  14. Functional Assessment of Cancer Therapy - Hepatobiliary Questionnaire (FACT-Hep) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

    FACT-Hep consists of 27-item FACT-G, and 18-item Hepatobiliary Subscale. FACT-Hep questionnaire uses 5-point Likert rating scale, range '0'-not at all to '4'. FACT-Hep total score ranges from 0 to 180, where highest score represents maximum achievable quality of life. Domains of FACT-G include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB) and Functional Well-Being (FWB). Hepatobiliary disease specific items include: swelling or cramps, losing weight, gastrointestinal (GI)-related questions, lack of energy, side effects, pain, fatigue, usual activities, jaundice, fevers, itching, taste of food and chills. Eight of the items (pain, back pain, stomach pain/discomfort, lack of energy, fatigue, nausea, weight loss and jaundice) make up FACT-Hepatobiliary Symptom Index (FHSI-8), and are considered to be symptoms specific to hepatobiliary cancer. Table below included mixed effect model estimated average based on all observed values/time points.

    Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date

  15. Functional Assessment of Cancer Therapy - General (FACT-G) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

    FACT-G is core questionnaire of Functional Assessment of Chronic Illness Therapy (FACIT) measurement system to evaluate QoL in cancer population. FACT-G consisted of 27 questions grouped in 4 domains of general Health-Related QoL (HRQoL): PWB, SWB, EWB and FWB; each ranging from 0 (not at all) to 4 (very much). FACT-G ranged between 0 and 108. Since questions could be reversed coded, as appropriate, before calculating FACT-G, 0 and 108 could be considered worst and best health states. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

    Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date

  16. Functional Assessment of Cancer Therapy (FACT)-Hepatobiliary Symptom Index-8 (FHSI-8) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

    The FACT-Hep includes the FACT-G and a hepatobiliary module. The hepatobiliary disease specific items include: swelling or cramps, losing weight, GI related questions, lack of energy, side effects, pain, fatigue, usual activities, jaundice, fevers, itching, taste of food and chills. Eight of the items (pain, back pain, stomach pain/discomfort, lack of energy, fatigue, nausea, weight loss, and jaundice) make up the FHSI-8, and are considered to be symptoms specific to hepatobiliary cancer. FHSI-8 total score ranges from 0 to 32 where "0" is a severely symptomatic participant and the highest score indicates an asymptomatic participant. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

    Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date

  17. Functional Assessment of Cancer Therapy-G (FACT-G) Subscales in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

    FACT-G is core questionnaire of Functional Assessment of Chronic Illness Therapy (FACIT) measurement system to evaluate QoL in cancer population. FACT-G consisted of 27 questions grouped in 4 domains of general HRQoL: PWB, SWB, EWB and FWB. Each of the individual subscale, except EWB has 7 items and each integer scored 0 to 4 making a maximum possible score of 28 (range 0 to 28). EWB has 6 items and each integer scored 0 to 4 making a maximum possible score of 24 (range 0 to 24). For all the 4 scales, higher values correspond to better health. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

    Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date

  18. Functional Assessment of Cancer Therapy - Hepatobiliary Cancer Subscale (FACT Hep-CS18) Questionnaire in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

    This subscale consists of 18 items rated on a scale from '0' - not at all to '4' - very much regarding how much each item was present in the last 7 days. FACT-Hep-CS18 total score ranges from 0 to 72. The higher score reflects better QoL or fewer symptoms. The 18 items of this scale are associated with hepatocellular carcinoma. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

    Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date

  19. Functional Assessment of Cancer Therapy - Hepatobiliary Cancer Trial Outcome Index (FACT Hep-TOI) Questionnaire in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

    The trial outcome index is defined to be the sum (PWB+FWB+HepCS), making it 32 items altogether. Each ranges from '0' - not at all to '4' - very much regarding how much each item was present in the last 7 days. FACT Hep -TOI total score ranges from 0 to 128, where the highest score represents a maximum achievable quality of life. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

    Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date

  20. Time to Deterioration (TTD) Based on the Composite Endpoint in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

    TTD analysis was performed for FHSI-8. Time to deterioration was defined as the time between date of randomization and date of the event.

    Time frame: From randomization to death or tumor progression or FHSI-8 mean score decrease >=3 points, whichever comes first

  21. EuroQoL (EQ-5D)- Health State Profile Utility Score in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

    Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date

  22. EuroQoL Visual Analogue Scale (EQ-VAS) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

    EQ-5D VAS in rates the participant's overall health status using values from 0 (worst imaginable) to 100 (best imaginable). The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

    Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date

  23. Number of Participants With Dose-Limiting Toxicities (DLTs) in Non-Randomized Portion

    Number of Child-Pugh Class B (score 7) participants with DLT was evaluated during Cycle 1 of treatment in the non-randomized portion of the study.

    Time frame: Cycle 1 (4 weeks)

  24. Number of Participants With Treatment-Emergent Adverse Events (AEs) in Non-Randomized Portion

    An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. The grade of an AE was determined according to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.

    Time frame: Up to 28 days after last dose of study drug (up to 6 years)

  25. Number of Participants With Treatment-Related Adverse Events (AEs) in Non-Randomized Portion

    Treatment-related AE was any untoward medical occurrence in a participant with causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The grade of an AE was determined according to CTCAE Version 3.0.

    Time frame: Up to 28 days after last dose of study drug (up to 6 years)

  26. Number of Participants With Treatment-Emergent Adverse Events (AEs) in Randomized Portion

    An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. The grade of an AE was determined according to CTCAE Version 3.0.

    Time frame: Up to 28 days after last dose of study drug (up to 6 years)

  27. Number of Participants With Treatment-Related Adverse Events (AEs) in Randomized Portion

    Treatment-related AE was any untoward medical occurrence in a participant with causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The grade of an AE was determined according to CTCAE Version 3.0.

    Time frame: Up to 28 days after last dose of study drug (up to 6 years)

07

Results

Posted May 27, 2015

Participant flow

Total 224 participants were enrolled in the study. Randomized portion enrolled 202 participants in 2 arms (134 in axitinib, 68 in placebo) in 70 centers (13 countries). Non-randomized portion enrolled 22 participants in 2 cohorts (15 in Child-Pugh Class A, 7 in Child-Pugh Class B score 7) according to Child-Pugh score in 13 centers (4 countries).

Participant flow — Overall Study
MilestoneChild-Pugh Class AChild-Pugh Class BAxitinibPlacebo
Started15713468
Completed0000
Not completed15713468
Withdrew: Participant refused further follow-up10112
Withdrew: Death14711254
Withdrew: Study terminated by sponsor00411
Withdrew: Lost to follow-up0011
Withdrew: Other unspecified0060

Outcome measures

PrimaryOverall Survival (OS) - Stratified Analysis, Randomized Portion

OS was defined as the time from the date of randomization to the date of death due to any cause. OS (in months) was calculated as (date of death - first randomization date +1)/30.4. For participants still alive at the time of the analysis, the OS time was censored on the last date they were known to be alive. All participants were followed up for survival at least every 3 months after discontinuing study treatment until at least two years after randomization of the last participant.

Time frame:
From randomization until at least two years after the last participant has been randomized (up to 6 years)
Reported as:
Median · months
Overall Survival (OS) - Stratified Analysis, Randomized Portion
monthsAxitinibPlacebo
Overall Survival (OS) - Stratified Analysis, Randomized Portion12.7 (10.2 to 14.9)9.7 (5.9 to 11.8)
Statistical analysis
  • Axitinib vs Placebo · Log Rank · p = 0.2872 (For the overall stratified analysis the p-value is from a 1-sided log-rank test of treatment stratified by tumor invasion and geographic region.) · Hazard ratio (hr): 0.907 · 95% CI 0.646 to 1.274Assuming proportional hazards, a hazard ratio less than (\<) 1 indicated reduction in hazard rate to favor Axitinib; hazard ratio greater than (\>) 1 indicated reduction to favor Placebo.
SecondaryProgression-Free Survival (PFS) - Stratified Analysis, Randomized Portion

PFS was defined as time from randomization to first documented objective tumor progression or to death due to any cause, whichever occurred first. PFS (in months) was calculated as (first event date - first randomization date +1)/30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was death). As per response evaluation criteria in solid tumors (RECIST) 1.1, progression was defined as greater than or equal to (\>=) 20% increase in sum of longest dimensions of target lesions or appearance of one or more new target lesions and unequivocal progression of existing non-target lesions, or appearance of 1 new non-target lesions. Participants discontinuing study treatment without documented evidence of PD were to be followed up at least every 8 weeks after discontinuing study treatment until disease progression, or initiation of another anticancer treatment.

Time frame:
Every 8 weeks until disease progression/death or start of new treatment or until at least two years after the last participant has been randomized, whatever occurs first
Reported as:
Median · months
Progression-Free Survival (PFS) - Stratified Analysis, Randomized Portion
monthsAxitinibPlacebo
Progression-Free Survival (PFS) - Stratified Analysis, Randomized Portion3.6 (2.3 to 4.6)1.9 (1.9 to 3.5)
Statistical analysis
  • Axitinib vs Placebo · Log Rank · p = 0.0039 (For the overall stratified analysis the p-value is from a 1-sided log-rank test of treatment stratified by tumor invasion and geographic region.) · Hazard ratio (hr): 0.618 · 95% CI 0.438 to 0.871Assuming proportional hazards, a hazard ratio \<1 indicated a reduction in hazard rate in favor of Axitinib; a hazard ratio \>1 indicated a reduction in favor of Placebo.
SecondaryObjective Response Rate (ORR) - Percentage of Participants With Objective Response by Stratified Analysis, Randomized Portion

ORR was defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) according to the RECIST 1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must decrease to normal (short axis \<10 millimetres \[mm\]). PR was defined as a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
Every 8 weeks until at least two years after the last participant has been randomized
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) - Percentage of Participants With Objective Response by Stratified Analysis, Randomized Portion
percentage of participantsAxitinibPlacebo
Objective Response Rate (ORR) - Percentage of Participants With Objective Response by Stratified Analysis, Randomized Portion9.7 (5.3 to 16.0)2.9 (0.4 to 10.2)
Statistical analysis
  • Axitinib vs Placebo · Cochran-Mantel-Haenszel · p = 0.0914 (ORR for the 2 treatment arms was compared with a significance level of 0.025 using Cochran-Mantel-Haenszel (CMH) test for stratified analyses.) · Risk ratio (rr): 3.172 · 95% CI 0.759 to 13.265Risk ratio and confidence interval (CI) were based on the Mantel-Haenszel estimator; risk ratio was adjusted for geographical region and vascular invasion and extra hepatic spread.
SecondaryTime to Tumor Progression (TTP) - Stratified Analysis, Randomized Portion

TTP was defined as the time from randomization to first documentation of objective tumor progression. If tumor progression data included more than 1 date, the first date was used. TTP (in months) was calculated as (first event date - first randomization date +1)/30.4.

Time frame:
Every 8 weeks until disease progression/death or start of new treatment or until at least two years after the last participant has been randomized, whatever occurs first
Reported as:
Median · months
Time to Tumor Progression (TTP) - Stratified Analysis, Randomized Portion
monthsAxitinibPlacebo
Time to Tumor Progression (TTP) - Stratified Analysis, Randomized Portion3.7 (2.8 to 5.6)1.9 (1.9 to 3.6)
Statistical analysis
  • Axitinib vs Placebo · Log Rank · p = 0.006 (For the overall stratified analysis the p-value is from a 1-sided log-rank test of treatment stratified by tumor invasion and geographic region.) · Hazard ratio (hr): 0.621 · 95% CI 0.434 to 0.889Assuming proportional hazards, a hazard ratio \<1 indicated a reduction in hazard rate in favor of Axitinib; a hazard ratio \>1 indicated a reduction in favor of Placebo.
SecondaryDuration of Response (DR) by Unstratified Analysis, Randomized Portion

DR was defined as the time from the first documentation of objective tumor response (CR or PR) that was subsequently confirmed to the first documentation of PD or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date was to be used. DR (in months) was to be calculated as (the end date for DR - first CR or PR that was subsequently confirmed +1)/30.4.

Time frame:
From objective response to date of progression or death
Reported as:
Median · months
Duration of Response (DR) by Unstratified Analysis, Randomized Portion
monthsAxitinibPlacebo
Duration of Response (DR) by Unstratified Analysis, Randomized Portion6.4 (3.7 to 9.3)NA (NA to NA)
SecondaryPercentage of Participants With Overall Clinical Benefit Response (CBR) - Stratified Analysis, Randomized Portion

CBR was defined as the percentage of participants with confirmed CR or confirmed PR or a best response of stable disease \>=8 weeks according to RECIST 1.1 criteria, relative to all randomized participants who had baseline measurable disease. Confirmed responses were defined as those that persisted on repeat imaging study \>=4 weeks after the initial documentation of response. Participants who did not have on study radiographic tumor re-evaluation or who died, progressed, or dropped out for any reason prior to reaching a CR, PR, or stable disease were counted as non-responders in the assessment of CBR. A participant who initially met the criteria for a PR and then subsequently became a confirmed CR was to be assigned a best response of CR.

Time frame:
From Baseline up to end of treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Clinical Benefit Response (CBR) - Stratified Analysis, Randomized Portion
percentage of participantsAxitinibPlacebo
Percentage of Participants With Overall Clinical Benefit Response (CBR) - Stratified Analysis, Randomized Portion31.3 (23.6 to 39.9)11.8 (5.2 to 21.9)
Statistical analysis
  • Axitinib vs Placebo · Cochran-Mantel-Haenszel · p = 0.0025 (For the overall stratified analysis the p-value is from Cochran-Mantel-Haenszel test of treatment stratified by geographical region and vascular invasion and extra hepatic spread.) · Risk ratio (rr): 2.650 · 95% CI 1.319 to 5.326Risk Ratio and CI based on the Mantel-Haenszel estimator; risk ratio was adjusted for geographical region and vascular invasion and extra hepatic spread.
SecondaryAxitinib Steady-State Pharmacokinetic (PK) Parameter - Maximum Observed Plasma Concentration (Cmax), Non-Randomized Portion

Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing.

Time frame:
Cycle 1 Day 15
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Axitinib Steady-State Pharmacokinetic (PK) Parameter - Maximum Observed Plasma Concentration (Cmax), Non-Randomized Portion
nanograms per milliliter (ng/mL)Child-Pugh Class AChild-Pugh Class B
Axitinib Steady-State Pharmacokinetic (PK) Parameter - Maximum Observed Plasma Concentration (Cmax), Non-Randomized Portion35.74 (21.84 to 58.50)21.16 (11.10 to 40.33)
SecondaryAxitinib Steady-State PK Parameter - Area Under the Plasma Concentration Versus Time Curve From 0 to 24 Hour (AUC0-24), Non-Randomized Portion

Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.

Time frame:
Cycle 1 Day 15
Reported as:
Geometric mean · nanograms*hour per milliliter (ng*hr/mL)
Axitinib Steady-State PK Parameter - Area Under the Plasma Concentration Versus Time Curve From 0 to 24 Hour (AUC0-24), Non-Randomized Portion
nanograms*hour per milliliter (ng*hr/mL)Child-Pugh Class AChild-Pugh Class B
Axitinib Steady-State PK Parameter - Area Under the Plasma Concentration Versus Time Curve From 0 to 24 Hour (AUC0-24), Non-Randomized Portion310.76 (175.02 to 551.75)316.20 (162.96 to 613.55)
SecondaryAxitinib Steady-State Pharmacokinetic Parameter - Time to First Occurrence of Cmax (Tmax), Non-Randomized Portion

Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing.

Time frame:
Cycle 1 Day 15
Reported as:
Median · hours
Axitinib Steady-State Pharmacokinetic Parameter - Time to First Occurrence of Cmax (Tmax), Non-Randomized Portion
hoursChild-Pugh Class AChild-Pugh Class B
Axitinib Steady-State Pharmacokinetic Parameter - Time to First Occurrence of Cmax (Tmax), Non-Randomized Portion2.50 (0.00 to 7.98)1.05 (0.00 to 4.00)
SecondaryAxitinib Steady-State Pharmacokinetic Parameter - Apparent Oral Clearance (CL/F), Non-Randomized Portion

Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.

Time frame:
Cycle 1 Day 15
Reported as:
Geometric mean · liters per hour (L/hr)
Axitinib Steady-State Pharmacokinetic Parameter - Apparent Oral Clearance (CL/F), Non-Randomized Portion
liters per hour (L/hr)Child-Pugh Class AChild-Pugh Class B
Axitinib Steady-State Pharmacokinetic Parameter - Apparent Oral Clearance (CL/F), Non-Randomized Portion32.18 (18.12 to 57.13)12.65 (6.52 to 24.55)
SecondaryAxitinib Steady-State Pharmacokinetic Parameter - Terminal Plasma Elimination Half-Life (t1/2), Non-Randomized Portion

Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.

Time frame:
Cycle 1 Day 15
Reported as:
Mean · hours
Axitinib Steady-State Pharmacokinetic Parameter - Terminal Plasma Elimination Half-Life (t1/2), Non-Randomized Portion
hoursChild-Pugh Class AChild-Pugh Class B
Axitinib Steady-State Pharmacokinetic Parameter - Terminal Plasma Elimination Half-Life (t1/2), Non-Randomized Portion4.12 ± 3.554.79 ± 2.42
SecondaryAxitinib Steady-State Pharmacokinetic Parameter - Apparent Oral Volume of Distribution of the Drug During the Elimination Phase (Vz/F), Non-Randomized Portion

Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. The PK parameter, Vz/F has been presented in this outcome measure. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.

Time frame:
Cycle 1 Day 15
Reported as:
Geometric mean · liters
Axitinib Steady-State Pharmacokinetic Parameter - Apparent Oral Volume of Distribution of the Drug During the Elimination Phase (Vz/F), Non-Randomized Portion
litersChild-Pugh Class AChild-Pugh Class B
Axitinib Steady-State Pharmacokinetic Parameter - Apparent Oral Volume of Distribution of the Drug During the Elimination Phase (Vz/F), Non-Randomized Portion150.01 ± 3.5581.16 ± 2.42
SecondaryConcentration of Soluble Proteins at Baseline in Randomized Portion

Plasma soluble proteins interleukin-6 (IL-6), E-Selectin, interleukin-8 (IL-8), hepatocyte growth factor (HGF), matrix metalloproteinase-2 (MMP-2), stem cell factor (SCF), angiopoietin-2 (Ang-2), vascular endothelial growth factor-A (VEGF-A), vascular endothelial growth factor-C (VEGF-C), soluble vascular endothelial growth factor receptor 2 (sVEGFR2), soluble vascular endothelial growth factor receptor 3 (sVEGFR3), stromal cell-derived factor-1 (SDF1), neutrophil gelatinase-associated lipocalin (NGAL), migration inhibitory factor (MIF), c-MET, regulated upon activation normal T cell expressed and presumably secreted (RANTES), and monocyte chemotactic protein-3 (MCP-3) were only measured in randomized participants.

Time frame:
Baseline
Reported as:
Mean · picograms per milliliter (pg/mL)
Concentration of Soluble Proteins at Baseline in Randomized Portion
picograms per milliliter (pg/mL)AxitinibPlacebo
IL-650.67 ± 102.8650.72 ± 106.74
E-Selectin52313.94 ± 32603.1855430.76 ± 26723.43
IL-833.35 ± 47.7227.23 ± 44.46
HGF478.84 ± 712.43406.06 ± 376.04
MMP-2355715.66 ± 137663.04350979.72 ± 146323.29
SCF1352.75 ± 1534.411439.71 ± 2260.89
Ang-2662.40 ± 623.87577.82 ± 354.42
VEGF-A102.56 ± 128.09173.59 ± 472.19
VEGF-CNA ± NANA ± NA
sVEGFR217675.76 ± 7218.9518273.65 ± 6836.16
sVEGFR3287429.28 ± 117583.24290338.69 ± 97830.36
SDF11190.08 ± 823.031150.10 ± 681.04
NGAL134861.80 ± 152492.96141383.00 ± 121747.35
MIF33057.15 ± 28256.0032302.99 ± 21485.01
c-MET ELISA1664.96 ± 834.361641.08 ± 704.38
RANTES26412.12 ± 38682.8126917.76 ± 27094.12
MCP-3NA ± NANA ± NA
SecondaryPercentage of Participants With Specific Micro-Ribonucleic Acid (miRNA) Transcript Present in Circulation in Randomized Portion

A 5 millilitres (mL) whole blood sample was collected from all randomized participants to evaluate the miRNA transcripts.

Time frame:
Baseline
Reported as:
Number · percentage of participants
Percentage of Participants With Specific Micro-Ribonucleic Acid (miRNA) Transcript Present in Circulation in Randomized Portion
percentage of participantsAxitinibPlacebo
hsa-let-7a-5p100.0100.0
hsa-let-7b-5p100.0100.0
hsa-let-7c100.0100.0
hsa-let-7d-5p100.0100.0
hsa-let-7f-5p100.0100.0
hsa-let-7g-5p100.0100.0
hsa-let-7i-5p100.0100.0
hsa-miR-103a-3p100.0100.0
hsa-miR-106b-5p100.0100.0
hsa-miR-107100.0100.0
hsa-miR-1202100.0100.0
hsa-miR-1207-5p100.0100.0
hsa-miR-1225-5p100.0100.0
hsa-miR-1234-5p100.0100.0
hsa-miR-1246100.0100.0
hsa-miR-125b-5p100.0100.0
hsa-miR-126-3p100.0100.0
hsa-miR-1260a100.0100.0
hsa-miR-1260b100.0100.0
hsa-miR-1268a100.0100.0
hsa-miR-1273g-3p100.0100.0
hsa-miR-1275100.0100.0
hsa-miR-128100.0100.0
hsa-miR-130a-3p100.0100.0
hsa-miR-130b-3p100.0100.0
hsa-miR-140-3p100.0100.0
hsa-miR-142-3p100.0100.0
hsa-miR-145-5p100.0100.0
hsa-miR-148a-3p100.0100.0
hsa-miR-148b-3p100.0100.0
hsa-miR-150-5p100.0100.0
hsa-miR-151a-3p100.0100.0
hsa-miR-151a-5p100.0100.0
hsa-miR-151b100.0100.0
hsa-miR-1587100.0100.0
hsa-miR-15a-5p100.0100.0
hsa-miR-15b-5p100.0100.0
hsa-miR-16-5p100.0100.0
hsa-miR-17-5p100.0100.0
hsa-miR-181a-5p100.0100.0
hsa-miR-182-5p100.0100.0
hsa-miR-183-5p100.0100.0
hsa-miR-185-5p100.0100.0
hsa-miR-186-5p100.0100.0
hsa-miR-191-5p100.0100.0
hsa-miR-1914-3p100.0100.0
hsa-miR-1915-3p100.0100.0
hsa-miR-192-5p100.0100.0
hsa-miR-194-5p100.0100.0
hsa-miR-197-3p100.0100.0
hsa-miR-197-5p100.0100.0
hsa-miR-19a-3p100.0100.0
hsa-miR-19b-3p100.0100.0
hsa-miR-20a-5p100.0100.0
hsa-miR-20b-5p100.0100.0
hsa-miR-21-5p100.0100.0
hsa-miR-210100.0100.0
hsa-miR-215100.0100.0
hsa-miR-22-3p100.0100.0
hsa-miR-222-3p100.0100.0
hsa-miR-223-3p100.0100.0
hsa-miR-23a-3p100.0100.0
hsa-miR-23b-3p100.0100.0
hsa-miR-24-3p100.0100.0
hsa-miR-25-3p100.0100.0
hsa-miR-26a-5p100.0100.0
hsa-miR-26b-5p100.0100.0
hsa-miR-2861100.0100.0
hsa-miR-29a-3p100.0100.0
hsa-miR-29b-3p100.0100.0
hsa-miR-29c-3p100.0100.0
hsa-miR-29c-5p100.0100.0
hsa-miR-30b-5p100.0100.0
hsa-miR-30c-5p100.0100.0
hsa-miR-30d-5p100.0100.0
hsa-miR-30e-5p100.0100.0
hsa-miR-3135b100.0100.0
hsa-miR-3162-5p100.0100.0
hsa-miR-3180-3p100.0100.0
hsa-miR-3195100.0100.0
hsa-miR-320a100.0100.0
hsa-miR-320b100.0100.0
hsa-miR-320c100.0100.0
hsa-miR-320d100.0100.0
hsa-miR-320e100.0100.0
hsa-miR-324-3p100.0100.0
hsa-miR-324-5p100.0100.0
hsa-miR-331-3p100.0100.0
hsa-miR-339-5p100.0100.0
hsa-miR-342-3p100.0100.0
hsa-miR-361-3p100.0100.0
hsa-miR-361-5p100.0100.0
hsa-miR-362-5p100.0100.0
hsa-miR-363-3p100.0100.0
hsa-miR-3651100.0100.0
hsa-miR-3656100.0100.0
hsa-miR-365a-3p100.0100.0
hsa-miR-3665100.0100.0
hsa-miR-3676-5p100.0100.0
hsa-miR-374b-5p100.0100.0
hsa-miR-378a-3p100.0100.0
hsa-miR-378i100.0100.0
hsa-miR-3940-5p100.0100.0
hsa-miR-3960100.0100.0
hsa-miR-423-3p100.0100.0
hsa-miR-425-5p100.0100.0
hsa-miR-4281100.0100.0
hsa-miR-4284100.0100.0
hsa-miR-4286100.0100.0
hsa-miR-4299100.0100.0
hsa-miR-4306100.0100.0
hsa-miR-4318100.0100.0
hsa-miR-4323100.0100.0
hsa-miR-4428100.0100.0
hsa-miR-4442100.0100.0
hsa-miR-4443100.0100.0
hsa-miR-4454100.0100.0
hsa-miR-4459100.0100.0
hsa-miR-4466100.0100.0
hsa-miR-4497100.0100.0
hsa-miR-4505100.0100.0
hsa-miR-4507100.0100.0
hsa-miR-4516100.0100.0
hsa-miR-451a100.0100.0
hsa-miR-4530100.0100.0
hsa-miR-4687-3p100.0100.0
hsa-miR-4713-3p100.0100.0
hsa-miR-4721100.0100.0
hsa-miR-4728-5p100.0100.0
hsa-miR-4732-3p100.0100.0
hsa-miR-4739100.0100.0
hsa-miR-4763-3p100.0100.0
hsa-miR-4787-5p100.0100.0
hsa-miR-4788100.0100.0
hsa-miR-484100.0100.0
hsa-miR-486-5p100.0100.0
hsa-miR-494100.0100.0
hsa-miR-5001-5p100.0100.0
hsa-miR-500a-3p100.0100.0
hsa-miR-500a-5p100.0100.0
hsa-miR-501-3p100.0100.0
hsa-miR-501-5p100.0100.0
hsa-miR-502-3p100.0100.0
hsa-miR-505-5p100.0100.0
hsa-miR-5100100.0100.0
hsa-miR-532-3p100.0100.0
hsa-miR-532-5p100.0100.0
hsa-miR-550a-3-5p100.0100.0
hsa-miR-550a-3p100.0100.0
hsa-miR-5739100.0100.0
hsa-miR-574-3p100.0100.0
hsa-miR-574-5p100.0100.0
hsa-miR-5787100.0100.0
hsa-miR-584-5p100.0100.0
hsa-miR-6085100.0100.0
hsa-miR-6087100.0100.0
hsa-miR-6088100.0100.0
hsa-miR-6089100.0100.0
hsa-miR-6090100.0100.0
hsa-miR-6125100.0100.0
hsa-miR-6127100.0100.0
hsa-miR-625-5p100.0100.0
hsa-miR-638100.0100.0
hsa-miR-642a-3p100.0100.0
hsa-miR-642b-3p100.0100.0
hsa-miR-652-3p100.0100.0
hsa-miR-660-5p100.0100.0
hsa-miR-664a-3p100.0100.0
hsa-miR-664b-3p100.0100.0
hsa-miR-6717-5p100.0100.0
hsa-miR-6724-5p100.0100.0
hsa-miR-7-5p100.0100.0
hsa-miR-762100.0100.0
hsa-miR-766-3p100.0100.0
hsa-miR-92a-3p100.0100.0
hsa-miR-93-3p100.0100.0
hsa-miR-93-5p100.0100.0
hsa-miR-937-5p100.0100.0
hsa-miR-940100.0100.0
hsa-miR-1228-3p99.1100.0
hsa-miR-1268b99.1100.0
hsa-miR-142-5p100.098.3
hsa-miR-27a-3p99.1100.0
hsa-miR-296-5p99.1100.0
hsa-miR-319699.1100.0
hsa-miR-319899.1100.0
hsa-miR-342-5p100.098.3
hsa-miR-3653100.098.3
hsa-miR-446599.1100.0
hsa-miR-451599.1100.0
hsa-miR-4653-3p99.1100.0
hsa-miR-4665-3p99.1100.0
hsa-miR-4746-3p99.1100.0
hsa-miR-505-3p100.098.3
hsa-miR-607399.1100.0
hsa-miR-612699.1100.0
hsa-miR-613299.1100.0
hsa-miR-616599.1100.0
hsa-miR-744-5p100.098.3
hsa-miR-87499.1100.0
hsa-miR-942100.098.3
hsa-miR-96-5p99.1100.0
hsa-miR-1238-3p98.2100.0
hsa-miR-1285-3p99.198.3
hsa-miR-130598.2100.0
hsa-miR-146a-5p98.2100.0
hsa-miR-15b-3p99.198.3
hsa-miR-17-3p98.2100.0
hsa-miR-195-5p99.198.3
hsa-miR-199a-5p99.198.3
hsa-miR-28-5p99.198.3
hsa-miR-30a-5p99.198.3
hsa-miR-340-3p99.198.3
hsa-miR-3679-5p99.198.3
hsa-miR-374a-5p99.198.3
hsa-miR-378a-5p99.198.3
hsa-miR-4433-5p98.2100.0
hsa-miR-454-3p99.198.3
hsa-miR-4685-5p99.198.3
hsa-miR-57598.2100.0
hsa-miR-606898.2100.0
hsa-miR-612498.2100.0
hsa-miR-613198.2100.0
hsa-miR-939-5p98.2100.0
hsa-miR-1234-3p99.196.6
hsa-miR-124998.298.3
hsa-miR-132-3p99.196.6
hsa-miR-30e-3p98.298.3
hsa-miR-32699.196.6
hsa-miR-374c-5p98.298.3
hsa-miR-427097.3100.0
hsa-miR-467297.3100.0
hsa-miR-474198.298.3
hsa-miR-6515-3p97.3100.0
hsa-miR-371b-5p97.398.3
hsa-miR-448596.4100.0
hsa-miR-451398.296.6
hsa-miR-454-5p98.296.6
hsa-miR-4716-3p96.4100.0
hsa-miR-5006-5p97.398.3
hsa-miR-606998.296.6
hsa-miR-101-3p97.396.6
hsa-miR-155-5p97.396.6
hsa-miR-16-2-3p98.294.9
hsa-miR-27b-3p98.294.9
hsa-miR-32898.294.9
hsa-miR-448696.498.3
hsa-miR-513a-5p96.498.3
hsa-miR-92b-3p98.294.9
hsa-miR-98-5p98.294.9
hsa-miR-18b-5p96.496.6
hsa-miR-191-3p97.394.9
hsa-miR-3200-5p97.394.9
hsa-miR-431397.394.9
hsa-miR-453296.496.6
hsa-miR-4787-3p97.394.9
hsa-miR-513b95.598.3
hsa-miR-550a-5p97.394.9
hsa-miR-5581-5p94.6100.0
hsa-miR-629-3p97.394.9
hsa-miR-629-5p94.6100.0
hsa-miR-7-1-3p98.293.2
hsa-miR-125a-3p94.698.3
hsa-miR-128197.393.2
hsa-miR-140-5p95.596.6
hsa-miR-144-5p96.494.9
hsa-let-7b-3p96.493.2
hsa-let-7f-1-3p95.594.9
hsa-miR-125a-5p96.493.2
hsa-miR-183-3p96.493.2
hsa-miR-3162-3p97.391.5
hsa-miR-33b-3p97.391.5
hsa-miR-466994.696.6
hsa-miR-502-5p96.493.2
hsa-miR-1304-3p97.389.8
hsa-miR-1306-5p95.593.2
hsa-miR-221-3p93.796.6
hsa-miR-4649-3p96.491.5
hsa-miR-4690-5p94.694.9
hsa-miR-62795.593.2
hsa-miR-99a-5p96.491.5
hsa-miR-18a-5p94.693.2
hsa-miR-211-3p94.693.2
hsa-miR-443095.591.5
hsa-miR-6508-5p95.591.5
hsa-miR-93395.591.5
hsa-miR-339-3p94.691.5
hsa-miR-624-5p95.589.8
hsa-miR-425-3p95.588.1
hsa-miR-519491.993.2
hsa-miR-6511b-3p92.891.5
hsa-let-7d-3p92.889.8
hsa-miR-129-2-3p92.889.8
hsa-miR-182592.889.8
hsa-miR-362-3p93.788.1
hsa-miR-66591.093.2
hsa-miR-149-5p92.888.1
hsa-miR-3620-5p91.091.5
hsa-miR-447890.191.5
hsa-miR-448492.886.4
hsa-miR-465690.191.5
hsa-miR-60291.988.1
hsa-miR-1233-1-5p89.291.5
hsa-miR-312589.291.5
hsa-miR-4725-5p91.088.1
hsa-miR-4732-5p91.088.1
hsa-miR-146b-5p92.883.1
hsa-miR-4659a-3p91.086.4
hsa-miR-6510-5p88.391.5
hsa-miR-1225-3p91.084.7
hsa-miR-153990.186.4
hsa-miR-188-5p88.389.8
hsa-miR-4758-3p91.084.7
hsa-miR-550b-2-5p91.983.1
hsa-miR-144-3p89.286.4
hsa-miR-431089.284.7
hsa-miR-4749-3p89.284.7
hsa-miR-1229-5p87.486.4
hsa-miR-128886.588.1
hsa-miR-3156-5p84.791.5
hsa-miR-2116-3p89.281.4
hsa-miR-4664-3p87.484.7
hsa-miR-23c87.483.1
hsa-miR-365285.686.4
hsa-miR-424-5p88.381.4
hsa-miR-4745-5p85.686.4
hsa-miR-197383.888.1
hsa-miR-429184.786.4
hsa-miR-3200-3p86.581.4
hsa-miR-4436b-5p84.784.7
hsa-miR-6512-5p82.988.1
hsa-miR-3613-3p86.578.0
hsa-miR-4793-5p81.188.1
hsa-miR-628-3p83.883.1
hsa-miR-118182.983.1
hsa-miR-364682.084.7
hsa-miR-431782.983.1
hsa-miR-568483.881.4
hsa-miR-1227-5p81.184.7
hsa-miR-3180-5p84.778.0
hsa-miR-4665-5p82.981.4
hsa-miR-129-1-3p82.081.4
hsa-miR-4652-3p82.979.7
hsa-miR-500b82.079.7
hsa-miR-181b-5p83.874.6
hsa-miR-3676-3p82.976.3
hsa-miR-671-5p77.586.4
hsa-miR-1185-1-3p78.483.1
hsa-miR-378d78.483.1
hsa-miR-1271-5p81.176.3
hsa-miR-4433-3p78.481.4
hsa-miR-56481.176.3
hsa-miR-6723-5p81.176.3
hsa-miR-100-5p82.971.2
hsa-miR-135a-3p77.581.4
hsa-miR-181a-2-3p80.276.3
hsa-miR-4666b78.479.7
hsa-miR-98-3p79.376.3
hsa-miR-3940-3p77.574.6
hsa-miR-513c-5p74.879.7
hsa-miR-63479.371.2
hsa-miR-4769-3p77.572.9
hsa-miR-6507-3p76.672.9
hsa-miR-390772.179.7
hsa-miR-463473.078.0
hsa-miR-56373.974.6
hsa-miR-892b73.974.6
hsa-miR-103a-2-5p74.871.2
hsa-miR-239273.972.9
hsa-miR-3127-5p72.176.3
hsa-miR-338-5p73.074.6
hsa-miR-3614-5p73.972.9
hsa-miR-449970.379.7
hsa-miR-3667-5p74.869.5
hsa-miR-129068.578.0
hsa-miR-130b-5p75.762.7
hsa-miR-444973.067.8
hsa-miR-4695-5p70.367.8
hsa-miR-427167.671.2
hsa-miR-465169.467.8
hsa-miR-340-5p63.174.6
hsa-miR-133b67.661.0
hsa-miR-199b-5p70.355.9
hsa-miR-200c-3p67.661.0
hsa-miR-425763.169.5
hsa-miR-150-3p62.269.5
hsa-miR-30c-1-3p68.557.6
hsa-miR-139-3p64.962.7
hsa-miR-625-3p62.267.8
hsa-miR-106b-3p67.654.2
hsa-miR-409-3p63.162.7
hsa-miR-1237-3p63.161.0
hsa-miR-5571-5p66.754.2
hsa-miR-652-5p63.161.0
hsa-miR-196b-5p61.362.7
hsa-miR-22-5p64.955.9
hsa-miR-338-3p64.055.9
hsa-miR-26b-3p62.255.9
hsa-miR-426155.967.8
hsa-miR-345-5p60.457.6
hsa-miR-10a-5p58.659.3
hsa-miR-317656.862.7
hsa-miR-1224-5p56.861.0
hsa-miR-446255.962.7
hsa-miR-4728-3p58.657.6
hsa-miR-193a-5p59.554.2
hsa-miR-664b-5p55.961.0
hsa-miR-314153.264.4
hsa-miR-607555.959.3
hsa-miR-608655.061.0
hsa-miR-99b-5p55.959.3
hsa-miR-1307-3p58.652.5
hsa-miR-148b-5p56.855.9
hsa-miR-15a-3p59.550.8
hsa-miR-6513-3p61.347.5
hsa-miR-590-5p54.157.6
hsa-miR-199a-3p52.359.3
hsa-miR-301a-3p55.052.5
hsa-miR-469851.459.3
hsa-miR-491-5p56.849.2
hsa-miR-4701-5p53.254.2
hsa-miR-57253.254.2
hsa-let-7e-5p52.354.2
hsa-miR-13452.354.2
hsa-miR-335-5p51.454.2
hsa-miR-4646-3p54.149.2
hsa-miR-446351.452.5
hsa-miR-569056.839.0
hsa-miR-197246.850.8
hsa-miR-769-5p48.647.5
hsa-miR-126-5p43.255.9
hsa-miR-192-3p52.339.0
hsa-miR-4800-5p42.352.5
hsa-miR-212-3p42.350.8
hsa-miR-5010-3p43.249.2
hsa-miR-64148.639.0
hsa-miR-364840.550.8
hsa-miR-548ai45.940.7
hsa-miR-3663-3p42.344.1
hsa-miR-429838.749.2
hsa-miR-4707-3p41.444.1
hsa-miR-1273e38.747.5
hsa-miR-487b36.949.2
hsa-miR-1227-3p40.540.7
hsa-miR-18a-3p43.235.6
hsa-miR-769-3p40.539.0
hsa-miR-59839.639.0
hsa-miR-1273f38.737.3
hsa-miR-663a38.737.3
hsa-miR-211036.939.0
hsa-miR-371a-5p34.242.4
hsa-miR-483-3p36.039.0
hsa-miR-5195-3p37.835.6
hsa-miR-654-3p35.135.6
hsa-miR-877-3p34.237.3
hsa-miR-3190-5p34.235.6
hsa-miR-4697-5p34.235.6
hsa-miR-61736.032.2
hsa-miR-432435.130.5
hsa-miR-453431.535.6
hsa-miR-4633-5p28.839.0
hsa-miR-453827.939.0
hsa-miR-664a-5p29.735.6
hsa-miR-431226.137.3
hsa-miR-607625.235.6
hsa-miR-5585-3p28.827.1
hsa-miR-125b-1-3p25.232.2
hsa-miR-4632-5p27.028.8
hsa-miR-139-5p27.925.4
hsa-miR-476733.315.3
hsa-miR-34a-5p27.922.0
hsa-miR-445525.227.1
hsa-miR-330-3p28.818.6
hsa-miR-118025.223.7
hsa-miR-193b-3p28.816.9
hsa-miR-478420.730.5
hsa-miR-4667-5p23.423.7
hsa-miR-660-3p23.423.7
hsa-miR-4731-3p22.523.7
hsa-miR-503-5p24.320.3
hsa-miR-378g18.027.1
hsa-miR-448119.823.7
hsa-miR-138-2-3p18.923.7
hsa-miR-146920.720.3
hsa-miR-432721.618.6
hsa-miR-1236-5p17.123.7
hsa-miR-15218.022.0
hsa-miR-21-3p18.920.3
hsa-miR-4697-3p16.225.4
hsa-miR-548aa17.123.7
hsa-miR-63619.818.6
hsa-miR-767-3p18.022.0
hsa-miR-468923.48.5
hsa-miR-3679-3p19.813.6
hsa-miR-432615.322.0
hsa-miR-227617.116.9
hsa-miR-313717.116.9
hsa-miR-473416.218.6
hsa-miR-181c-5p18.013.6
hsa-miR-92117.115.3
hsa-miR-3688-3p15.316.9
hsa-miR-427415.316.9
hsa-miR-4758-5p16.213.6
hsa-miR-5010-5p15.315.3
hsa-miR-448813.516.9
hsa-miR-483-5p14.415.3
hsa-miR-542-5p15.313.6
hsa-miR-62311.720.3
hsa-miR-6509.923.7
hsa-miR-318811.718.6
hsa-miR-378b10.820.3
hsa-miR-576-5p12.616.9
hsa-miR-20a-3p15.310.2
hsa-miR-448715.310.2
hsa-miR-197612.613.6
hsa-miR-3605-3p12.613.6
hsa-miR-46479.918.6
hsa-miR-4700-3p11.715.3
hsa-miR-6503-3p12.613.6
hsa-miR-361510.813.6
hsa-miR-424-3p10.813.6
hsa-miR-463611.711.9
hsa-miR-4646-5p9.016.9
hsa-miR-361012.68.5
hsa-miR-5579.913.6
hsa-miR-71814.45.1
hsa-miR-193b-5p9.013.6
hsa-miR-3692-5p12.66.8
hsa-miR-509-3-5p11.78.5
hsa-miR-147010.88.5
hsa-miR-28-3p8.113.6
hsa-miR-378f10.88.5
hsa-miR-42526.316.9
hsa-miR-441711.76.8
hsa-miR-449810.88.5
hsa-miR-491-3p8.113.6
hsa-miR-495-3p7.215.3
hsa-miR-509612.65.1
hsa-miR-1229-3p6.315.3
hsa-miR-299-5p6.315.3
hsa-miR-31386.315.3
hsa-miR-335-3p8.111.9
hsa-miR-3682-3p8.111.9
hsa-miR-485-3p8.111.9
hsa-miR-6307.213.6
hsa-miR-9369.010.2
hsa-miR-101-5p10.85.1
hsa-miR-122-5p9.96.8
hsa-miR-4446-3p5.415.3
hsa-miR-45188.110.2
hsa-miR-4640-3p6.313.6
hsa-miR-51898.110.2
hsa-miR-61298.110.2
hsa-miR-14718.18.5
hsa-miR-29b-2-5p8.18.5
hsa-miR-5003-5p5.413.6
hsa-miR-1273c6.310.2
hsa-miR-190a9.05.1
hsa-miR-3675-3p8.16.8
hsa-miR-6511b-5p5.411.9
hsa-miR-12914.511.9
hsa-miR-3934-5p4.511.9
hsa-miR-47377.26.8
hsa-miR-486-3p6.38.5
hsa-miR-5580-3p2.715.3
hsa-miR-671-3p7.26.8
hsa-miR-154-5p6.36.8
hsa-miR-3158-5p7.25.1
hsa-miR-337-3p3.611.9
hsa-miR-363-5p4.510.2
hsa-miR-376a-3p3.611.9
hsa-miR-51903.611.9
hsa-miR-57016.36.8
hsa-miR-770-5p3.611.9
hsa-miR-1226-5p3.610.2
hsa-miR-12676.35.1
hsa-miR-1306-3p6.35.1
hsa-miR-31544.58.5
hsa-miR-3293.610.2
hsa-miR-4659b-3p7.23.4
hsa-miR-61343.610.2
hsa-miR-181a-3p4.56.8
hsa-miR-18275.45.1
hsa-miR-39262.710.2
hsa-miR-6624.56.8
hsa-miR-127-3p4.55.1
hsa-miR-148a-5p3.66.8
hsa-miR-18b-3p3.66.8
hsa-miR-202-3p2.78.5
hsa-miR-43252.78.5
hsa-miR-46735.43.4
hsa-miR-47306.31.7
hsa-miR-4894.55.1
hsa-miR-584-3p4.55.1
hsa-miR-6720-3p1.810.2
hsa-let-7i-3p5.41.7
hsa-miR-1307-5p3.65.1
hsa-miR-204-5p4.53.4
hsa-miR-218-5p4.53.4
hsa-miR-378e3.65.1
hsa-miR-39112.76.8
hsa-miR-5433.65.1
hsa-miR-57033.65.1
hsa-miR-589-3p3.65.1
hsa-miR-885-5p1.88.5
hsa-let-7g-3p3.63.4
hsa-miR-1185-2-3p4.51.7
hsa-miR-1238-5p3.63.4
hsa-miR-19b-1-5p3.63.4
hsa-miR-3130-5p2.75.1
hsa-miR-31633.63.4
hsa-miR-377-3p2.75.1
hsa-miR-4212.75.1
hsa-miR-4419a2.75.1
hsa-miR-44253.63.4
hsa-miR-44703.63.4
hsa-miR-45392.75.1
hsa-miR-516a-5p3.63.4
hsa-miR-6104.51.7
hsa-miR-628-5p3.63.4
hsa-miR-99b-3p2.75.1
hsa-let-7f-2-3p2.73.4
hsa-miR-193a-3p0.96.8
hsa-miR-195-3p2.73.4
hsa-miR-221-5p3.61.7
hsa-miR-223-5p4.50.0
hsa-miR-23a-5p1.85.1
hsa-miR-25-5p1.85.1
hsa-miR-3616-3p0.96.8
hsa-miR-376c-3p1.85.1
hsa-miR-4701-3p2.73.4
hsa-miR-4743-5p1.85.1
hsa-miR-5008-5p1.85.1
hsa-miR-570-3p2.73.4
hsa-miR-5951.85.1
hsa-miR-6716-3p3.61.7
hsa-miR-8872.73.4
hsa-miR-12990.95.1
hsa-miR-133a2.71.7
hsa-miR-1981.83.4
hsa-miR-3622b-5p0.95.1
hsa-miR-373-5p3.60.0
hsa-miR-39170.95.1
hsa-miR-409-5p1.83.4
hsa-miR-44402.71.7
hsa-miR-45140.95.1
hsa-miR-45350.95.1
hsa-miR-4668-5p0.95.1
hsa-miR-4776-5p0.95.1
hsa-miR-4793-3p2.71.7
hsa-miR-542-3p0.95.1
hsa-miR-548am-5p1.83.4
hsa-miR-548q1.83.4
hsa-miR-582-5p2.71.7
hsa-miR-654-5p1.83.4
hsa-miR-758-3p2.71.7
hsa-miR-7600.06.8
hsa-miR-7651.83.4
hsa-miR-875-5p1.83.4
hsa-miR-106a-3p2.70.0
hsa-miR-1236-3p0.05.1
hsa-miR-1255b-5p1.81.7
hsa-miR-181c-3p2.70.0
hsa-miR-26a-2-3p0.93.4
hsa-miR-2980.93.4
hsa-miR-3194-5p0.93.4
hsa-miR-3620-3p1.81.7
hsa-miR-374a-3p1.81.7
hsa-miR-411-3p1.81.7
hsa-miR-44750.93.4
hsa-miR-44760.93.4
hsa-miR-4716-5p1.81.7
hsa-miR-4762-3p1.81.7
hsa-miR-544a1.81.7
hsa-miR-548d-5p1.81.7
hsa-miR-561-3p1.81.7
hsa-miR-56952.70.0
hsa-miR-5801.81.7
hsa-miR-6121.81.7
hsa-miR-6220.93.4
hsa-miR-6701.81.7
hsa-miR-744-3p1.81.7
hsa-let-7a-3p0.91.7
hsa-miR-1255a0.91.7
hsa-miR-12700.91.7
hsa-miR-185-3p0.03.4
hsa-miR-186-3p0.03.4
hsa-miR-187-5p0.91.7
hsa-miR-194-3p1.80.0
hsa-miR-200b-5p0.91.7
hsa-miR-20520.03.4
hsa-miR-224-5p0.91.7
hsa-miR-2964a-5p0.91.7
hsa-miR-29b-1-5p0.91.7
hsa-miR-30d-3p0.03.4
hsa-miR-3150b-5p1.80.0
hsa-miR-3184-3p0.91.7
hsa-miR-32-3p0.91.7
hsa-miR-323a-3p1.80.0
hsa-miR-3663-5p1.80.0
hsa-miR-3700.91.7
hsa-miR-376a-5p0.91.7
hsa-miR-381-3p0.91.7
hsa-miR-39240.03.4
hsa-miR-39450.91.7
hsa-miR-422a1.80.0
hsa-miR-42890.91.7
hsa-miR-432-3p0.03.4
hsa-miR-44680.91.7
hsa-miR-452-3p0.91.7
hsa-miR-452-5p0.03.4
hsa-miR-4714-5p0.91.7
hsa-miR-5041.80.0
hsa-miR-50880.03.4
hsa-miR-518b0.91.7
hsa-miR-545-3p0.91.7
hsa-miR-545-5p0.91.7
hsa-miR-548at-5p0.91.7
hsa-miR-556-3p0.91.7
hsa-miR-5590.03.4
hsa-miR-56860.91.7
hsa-miR-5692a0.03.4
hsa-miR-5860.91.7
hsa-miR-590-3p1.80.0
hsa-miR-6010.91.7
hsa-miR-6070.91.7
hsa-miR-6190.03.4
hsa-miR-624-3p1.80.0
hsa-miR-642a-5p0.91.7
hsa-miR-6450.91.7
hsa-miR-6680.91.7
hsa-miR-6722-3p1.80.0
hsa-miR-675-5p0.91.7
hsa-miR-888-3p0.91.7
hsa-miR-937-3p0.91.7
hsa-miR-939-3p0.91.7
hsa-miR-10b-3p0.01.7
hsa-miR-10b-5p0.01.7
hsa-miR-11830.01.7
hsa-miR-12080.01.7
hsa-miR-1226-3p0.01.7
hsa-miR-1228-5p0.01.7
hsa-miR-124-3p0.90.0
hsa-miR-124-5p0.01.7
hsa-miR-1247-3p0.90.0
hsa-miR-12610.01.7
hsa-miR-1269a0.01.7
hsa-miR-1273d0.90.0
hsa-miR-1285-5p0.01.7
hsa-miR-12870.01.7
hsa-miR-12960.01.7
hsa-miR-143-3p0.90.0
hsa-miR-15380.01.7
hsa-miR-16-1-3p0.90.0
hsa-miR-1840.90.0
hsa-miR-188-3p0.90.0
hsa-miR-1909-5p0.01.7
hsa-miR-19100.01.7
hsa-miR-196a-3p0.90.0
hsa-miR-19a-5p0.01.7
hsa-miR-19b-2-5p0.90.0
hsa-miR-205-5p0.90.0
hsa-miR-2060.01.7
hsa-miR-20b-3p0.90.0
hsa-miR-2115-5p0.90.0
hsa-miR-218-1-3p0.01.7
hsa-miR-218-2-3p0.90.0
hsa-miR-2277-3p0.01.7
hsa-miR-2681-3p0.90.0
hsa-miR-26a-1-3p0.90.0
hsa-miR-27b-5p0.01.7
hsa-miR-2970.01.7
hsa-miR-29a-5p0.01.7
hsa-miR-3000.90.0
hsa-miR-301b0.90.0
hsa-miR-302b-3p0.01.7
hsa-miR-30a-3p0.90.0
hsa-miR-31320.01.7
hsa-miR-31490.01.7
hsa-miR-3157-5p0.01.7
hsa-miR-31610.01.7
hsa-miR-32-5p0.90.0
hsa-miR-330-5p0.90.0
hsa-miR-33a-3p0.90.0
hsa-miR-33b-5p0.01.7
hsa-miR-34c-3p0.01.7
hsa-miR-3591-3p0.01.7
hsa-miR-3607-3p0.90.0
hsa-miR-36540.01.7
hsa-miR-36660.01.7
hsa-miR-367-5p0.90.0
hsa-miR-374b-3p0.90.0
hsa-miR-379-3p0.90.0
hsa-miR-380-5p0.90.0
hsa-miR-39350.01.7
hsa-miR-39370.01.7
hsa-miR-3942-3p0.90.0
hsa-miR-39760.01.7
hsa-miR-4100.01.7
hsa-miR-42590.01.7
hsa-miR-42720.01.7
hsa-miR-42900.01.7
hsa-miR-42940.01.7
hsa-miR-431-5p0.01.7
hsa-miR-44200.90.0
hsa-miR-44220.01.7
hsa-miR-44890.01.7
hsa-miR-45000.90.0
hsa-miR-450a-5p0.90.0
hsa-miR-450b-3p0.01.7
hsa-miR-451b0.90.0
hsa-miR-4520b-3p0.01.7
hsa-miR-4639-3p0.90.0
hsa-miR-46480.01.7
hsa-miR-46570.01.7
hsa-miR-4677-3p0.90.0
hsa-miR-4677-5p0.90.0
hsa-miR-4685-3p0.90.0
hsa-miR-4694-3p0.01.7
hsa-miR-4695-3p0.01.7
hsa-miR-4707-5p0.01.7
hsa-miR-47100.01.7
hsa-miR-4723-3p0.90.0
hsa-miR-4726-5p0.01.7
hsa-miR-4733-3p0.01.7
hsa-miR-4733-5p0.90.0
hsa-miR-47360.01.7
hsa-miR-4740-5p0.01.7
hsa-miR-4755-3p0.01.7
hsa-miR-4762-5p0.01.7
hsa-miR-4763-5p0.01.7
hsa-miR-47850.01.7
hsa-miR-47920.90.0
hsa-miR-4800-3p0.90.0
hsa-miR-493-5p0.01.7
hsa-miR-5007-3p0.90.0
hsa-miR-5011-5p0.90.0
hsa-miR-50870.01.7
hsa-miR-50930.01.7
hsa-miR-513a-3p0.01.7
hsa-miR-513c-3p0.01.7
hsa-miR-517c-3p0.01.7
hsa-miR-518a-5p0.01.7
hsa-miR-5196-3p0.90.0
hsa-miR-520c-3p0.90.0
hsa-miR-541-3p0.01.7
hsa-miR-548a-3p0.90.0
hsa-miR-548ap-3p0.90.0
hsa-miR-548d-3p0.90.0
hsa-miR-548e0.90.0
hsa-miR-5520.90.0
hsa-miR-5580.01.7
hsa-miR-5591-3p0.01.7
hsa-miR-5681b0.90.0
hsa-miR-5692b0.90.0
hsa-miR-5692c0.90.0
hsa-miR-5710.01.7
hsa-miR-5880.90.0
hsa-miR-589-5p0.90.0
hsa-miR-593-3p0.90.0
hsa-miR-5970.01.7
hsa-miR-6090.90.0
hsa-miR-615-3p0.01.7
hsa-miR-615-5p0.01.7
hsa-miR-616-5p0.90.0
hsa-miR-6180.01.7
hsa-miR-6210.90.0
hsa-miR-6310.01.7
hsa-miR-6330.01.7
hsa-miR-6370.01.7
hsa-miR-6390.90.0
hsa-miR-642b-5p0.90.0
hsa-miR-6460.90.0
hsa-miR-6509-3p0.90.0
hsa-miR-6510.90.0
hsa-miR-6511a-3p0.01.7
hsa-miR-6570.90.0
hsa-miR-6722-5p0.01.7
hsa-miR-708-5p0.90.0
hsa-miR-767-5p0.90.0
hsa-miR-875-3p0.01.7
hsa-miR-876-5p0.90.0
hsa-miR-877-5p0.90.0
hsa-miR-891a0.90.0
hsa-miR-9200.90.0
hsa-miR-9220.90.0
hsa-miR-9240.01.7
hsa-miR-92a-2-5p0.90.0
hsa-miR-9350.90.0
hsa-miR-9380.01.7
hsa-miR-9430.90.0
hsa-miR-423-5p100.0100.0
SecondaryFunctional Assessment of Cancer Therapy - Hepatobiliary Questionnaire (FACT-Hep) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

FACT-Hep consists of 27-item FACT-G, and 18-item Hepatobiliary Subscale. FACT-Hep questionnaire uses 5-point Likert rating scale, range '0'-not at all to '4'. FACT-Hep total score ranges from 0 to 180, where highest score represents maximum achievable quality of life. Domains of FACT-G include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB) and Functional Well-Being (FWB). Hepatobiliary disease specific items include: swelling or cramps, losing weight, gastrointestinal (GI)-related questions, lack of energy, side effects, pain, fatigue, usual activities, jaundice, fevers, itching, taste of food and chills. Eight of the items (pain, back pain, stomach pain/discomfort, lack of energy, fatigue, nausea, weight loss and jaundice) make up FACT-Hepatobiliary Symptom Index (FHSI-8), and are considered to be symptoms specific to hepatobiliary cancer. Table below included mixed effect model estimated average based on all observed values/time points.

Time frame:
Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Reported as:
Least squares mean · units on a scale
Functional Assessment of Cancer Therapy - Hepatobiliary Questionnaire (FACT-Hep) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
units on a scaleAxitinibPlacebo
Functional Assessment of Cancer Therapy - Hepatobiliary Questionnaire (FACT-Hep) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model123.33 (120.17 to 126.50)135.22 (129.17 to 141.27)
Statistical analysis
  • Axitinib vs Placebo · Longitudinal mixed effect analysis · p = 0.0006 (No adjustment made for multiple comparisons.) · Mean difference (final values): -11.89 · 95% CI -18.70 to -5.08
SecondaryFunctional Assessment of Cancer Therapy - General (FACT-G) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

FACT-G is core questionnaire of Functional Assessment of Chronic Illness Therapy (FACIT) measurement system to evaluate QoL in cancer population. FACT-G consisted of 27 questions grouped in 4 domains of general Health-Related QoL (HRQoL): PWB, SWB, EWB and FWB; each ranging from 0 (not at all) to 4 (very much). FACT-G ranged between 0 and 108. Since questions could be reversed coded, as appropriate, before calculating FACT-G, 0 and 108 could be considered worst and best health states. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

Time frame:
Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Reported as:
Least squares mean · units on a scale
Functional Assessment of Cancer Therapy - General (FACT-G) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
units on a scaleAxitinibPlacebo
Functional Assessment of Cancer Therapy - General (FACT-G) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model71.20 (69.00 to 73.41)78.81 (74.68 to 82.93)
Statistical analysis
  • Axitinib vs Placebo · Longitudinal mixed effect analysis · p = 0.0014 (No adjustment made for multiple comparisons.) · Mean difference (final values): -7.60 · 95% CI -12.27 to -2.94
SecondaryFunctional Assessment of Cancer Therapy (FACT)-Hepatobiliary Symptom Index-8 (FHSI-8) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

The FACT-Hep includes the FACT-G and a hepatobiliary module. The hepatobiliary disease specific items include: swelling or cramps, losing weight, GI related questions, lack of energy, side effects, pain, fatigue, usual activities, jaundice, fevers, itching, taste of food and chills. Eight of the items (pain, back pain, stomach pain/discomfort, lack of energy, fatigue, nausea, weight loss, and jaundice) make up the FHSI-8, and are considered to be symptoms specific to hepatobiliary cancer. FHSI-8 total score ranges from 0 to 32 where "0" is a severely symptomatic participant and the highest score indicates an asymptomatic participant. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

Time frame:
Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Reported as:
Least squares mean · units on a scale
Functional Assessment of Cancer Therapy (FACT)-Hepatobiliary Symptom Index-8 (FHSI-8) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
units on a scaleAxitinibPlacebo
Functional Assessment of Cancer Therapy (FACT)-Hepatobiliary Symptom Index-8 (FHSI-8) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model23.42 (22.77 to 24.07)26.69 (25.35 to 28.03)
Statistical analysis
  • Axitinib vs Placebo · Longitudinal mixed effect analysis · p = <0.0001 (No adjustment made for multiple comparisons.) · Mean difference (final values): -3.27 · 95% CI -4.76 to -1.78
SecondaryFunctional Assessment of Cancer Therapy-G (FACT-G) Subscales in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

FACT-G is core questionnaire of Functional Assessment of Chronic Illness Therapy (FACIT) measurement system to evaluate QoL in cancer population. FACT-G consisted of 27 questions grouped in 4 domains of general HRQoL: PWB, SWB, EWB and FWB. Each of the individual subscale, except EWB has 7 items and each integer scored 0 to 4 making a maximum possible score of 28 (range 0 to 28). EWB has 6 items and each integer scored 0 to 4 making a maximum possible score of 24 (range 0 to 24). For all the 4 scales, higher values correspond to better health. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

Time frame:
Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Reported as:
Least squares mean · units on a scale
Functional Assessment of Cancer Therapy-G (FACT-G) Subscales in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
units on a scaleAxitinibPlacebo
PWB19.39 (18.72 to 20.07)23.13 (21.76 to 24.50)
SWB18.94 (18.05 to 19.83)20.21 (18.66 to 21.77)
EWB17.23 (16.63 to 17.84)17.71 (16.54 to 18.89)
FWB15.76 (14.88 to 16.65)17.83 (16.19 to 19.47)
Statistical analysis
  • Axitinib vs Placebo · Longitudinal mixed effect analysis · p = <0.0001 (No adjustment made for multiple comparisons.) · Mean difference (final values): -3.74 · 95% CI -5.26 to -2.21
  • Axitinib vs Placebo · Longitudinal mixed effect analysis · p = 0.1642 (No adjustment made for multiple comparisons.) · Mean difference (final values): -1.27 · 95% CI -3.07 to 0.52
  • Axitinib vs Placebo · Longitudinal mixed effect analysis · p = 0.4759 (No adjustment made for multiple comparisons.) · Mean difference (final values): -0.48 · 95% CI -1.80 to 0.84
  • Axitinib vs Placebo · Longitudinal mixed effect analysis · p = 0.0288 (No adjustment made for multiple comparisons.) · Mean difference (final values): -2.07 · 95% CI -3.92 to -0.21
SecondaryFunctional Assessment of Cancer Therapy - Hepatobiliary Cancer Subscale (FACT Hep-CS18) Questionnaire in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

This subscale consists of 18 items rated on a scale from '0' - not at all to '4' - very much regarding how much each item was present in the last 7 days. FACT-Hep-CS18 total score ranges from 0 to 72. The higher score reflects better QoL or fewer symptoms. The 18 items of this scale are associated with hepatocellular carcinoma. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

Time frame:
Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Reported as:
Least squares mean · units on a scale
Functional Assessment of Cancer Therapy - Hepatobiliary Cancer Subscale (FACT Hep-CS18) Questionnaire in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
units on a scaleAxitinibPlacebo
Functional Assessment of Cancer Therapy - Hepatobiliary Cancer Subscale (FACT Hep-CS18) Questionnaire in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model51.78 (50.46 to 53.10)56.74 (54.08 to 59.39)
Statistical analysis
  • Axitinib vs Placebo · Longitudinal mixed effect analysis · p = 0.0011 (No adjustment made for multiple comparisons.) · Mean difference (final values): -4.96 · 95% CI -7.93 to -1.99
SecondaryFunctional Assessment of Cancer Therapy - Hepatobiliary Cancer Trial Outcome Index (FACT Hep-TOI) Questionnaire in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

The trial outcome index is defined to be the sum (PWB+FWB+HepCS), making it 32 items altogether. Each ranges from '0' - not at all to '4' - very much regarding how much each item was present in the last 7 days. FACT Hep -TOI total score ranges from 0 to 128, where the highest score represents a maximum achievable quality of life. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

Time frame:
Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Reported as:
Least squares mean · units on a scale
Functional Assessment of Cancer Therapy - Hepatobiliary Cancer Trial Outcome Index (FACT Hep-TOI) Questionnaire in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
units on a scaleAxitinibPlacebo
Functional Assessment of Cancer Therapy - Hepatobiliary Cancer Trial Outcome Index (FACT Hep-TOI) Questionnaire in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model87.28 (84.98 to 89.58)97.73 (93.24 to 102.23)
Statistical analysis
  • Axitinib vs Placebo · Longitudinal mixed effect analysis · p = <0.0001 (No adjustment made for multiple comparisons.) · Mean difference (final values): -10.45 · 95% CI -15.49 to -5.42
SecondaryTime to Deterioration (TTD) Based on the Composite Endpoint in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

TTD analysis was performed for FHSI-8. Time to deterioration was defined as the time between date of randomization and date of the event.

Time frame:
From randomization to death or tumor progression or FHSI-8 mean score decrease >=3 points, whichever comes first
Reported as:
Median · months
Time to Deterioration (TTD) Based on the Composite Endpoint in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
monthsAxitinibPlacebo
Time to Deterioration (TTD) Based on the Composite Endpoint in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model1.9 (1.8 to 1.9)1.9 (1.8 to 2.7)
Statistical analysis
  • Axitinib vs Placebo · 1-sided, unstratified log-rank test · p = 0.9182 (The p-value is from a 1-sided log-rank test.) · Hazard ratio (hr): 1.252 · 95% CI 0.923 to 1.698Assuming proportional hazards, a hazard ratio \<1 indicates reduction in hazard rate to favor Axitinib, hazard ratio \>1 indicates reduction to favor Placebo.
SecondaryEuroQoL (EQ-5D)- Health State Profile Utility Score in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

Time frame:
Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Reported as:
Least squares mean · units on a scale
EuroQoL (EQ-5D)- Health State Profile Utility Score in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
units on a scaleAxitinibPlacebo
EuroQoL (EQ-5D)- Health State Profile Utility Score in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model0.67 (0.63 to 0.70)0.79 (0.72 to 0.86)
Statistical analysis
  • Axitinib vs Placebo · Longitudinal mixed effect analysis · p = 0.0024 · Mean difference (final values): -0.12 · 95% CI -0.20 to -0.04
SecondaryEuroQoL Visual Analogue Scale (EQ-VAS) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model

EQ-5D VAS in rates the participant's overall health status using values from 0 (worst imaginable) to 100 (best imaginable). The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.

Time frame:
Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Reported as:
Least squares mean · units on a scale
EuroQoL Visual Analogue Scale (EQ-VAS) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
units on a scaleAxitinibPlacebo
EuroQoL Visual Analogue Scale (EQ-VAS) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model68.67 (66.11 to 71.23)75.70 (70.40 to 81.00)
Statistical analysis
  • Axitinib vs Placebo · Longitudinal mixed effect analysis · p = 0.0193 · Mean difference (final values): -7.03 · 95% CI -12.91 to -1.15
SecondaryNumber of Participants With Dose-Limiting Toxicities (DLTs) in Non-Randomized Portion

Number of Child-Pugh Class B (score 7) participants with DLT was evaluated during Cycle 1 of treatment in the non-randomized portion of the study.

Time frame:
Cycle 1 (4 weeks)
Reported as:
Number · participants
Number of Participants With Dose-Limiting Toxicities (DLTs) in Non-Randomized Portion
participantsChild-Pugh Class AChild-Pugh Class B
Number of Participants With Dose-Limiting Toxicities (DLTs) in Non-Randomized Portion—2
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) in Non-Randomized Portion

An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. The grade of an AE was determined according to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.

Time frame:
Up to 28 days after last dose of study drug (up to 6 years)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) in Non-Randomized Portion
participantsChild-Pugh Class AChild-Pugh Class B
Participants with AEs157
Participants with SAEs103
Participants >=Grade 3 AEs135
Participants Grade 5 AEs41
SecondaryNumber of Participants With Treatment-Related Adverse Events (AEs) in Non-Randomized Portion

Treatment-related AE was any untoward medical occurrence in a participant with causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The grade of an AE was determined according to CTCAE Version 3.0.

Time frame:
Up to 28 days after last dose of study drug (up to 6 years)
Reported as:
Number · participants
Number of Participants With Treatment-Related Adverse Events (AEs) in Non-Randomized Portion
participantsChild-Pugh Class AChild-Pugh Class B
Participants with AEs14 ± 3.556 ± 2.42
Participants with SAEs22
Participants ≥Grade 3 AEs94
Participants Grade 5 AEs00
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) in Randomized Portion

An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. The grade of an AE was determined according to CTCAE Version 3.0.

Time frame:
Up to 28 days after last dose of study drug (up to 6 years)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) in Randomized Portion
participantsAxitinibPlacebo
Participants with AEs13163
Participants with SAEs6216
Participants with Grade >=3 AEs10926
Participants with Grade 5 AEs168
SecondaryNumber of Participants With Treatment-Related Adverse Events (AEs) in Randomized Portion

Treatment-related AE was any untoward medical occurrence in a participant with causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The grade of an AE was determined according to CTCAE Version 3.0.

Time frame:
Up to 28 days after last dose of study drug (up to 6 years)
Reported as:
Number · participants
Number of Participants With Treatment-Related Adverse Events (AEs) in Randomized Portion
participantsAxitinibPlacebo
Participants with AEs12840
Participants with SAEs241
Participants with Grade >=3 AEs9012
Participants with Grade 5 AEs10

Adverse events

Collected over Baseline up to follow-up visit (up to 6 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Child-Pugh Class A—10/15 (66.7%)15/15 (100%)
Child-Pugh Class B—3/7 (42.9%)7/7 (100%)
Axitinib—62/133 (46.6%)130/133 (97.7%)
Placebo—16/68 (23.5%)55/68 (80.9%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventChild-Pugh Class AChild-Pugh Class BAxitinibPlacebo
Disease progressionGeneral disorders3/150/78/1334/68
Varices oesophagealGastrointestinal disorders0/151/70/1330/68
Peritonitis bacterialInfections and infestations0/151/70/1330/68
Electrolyte imbalanceMetabolism and nutrition disorders0/151/70/1330/68
HyponatraemiaMetabolism and nutrition disorders0/151/70/1330/68
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/151/71/1330/68
EncephalopathyNervous system disorders0/151/72/1330/68
Cholecystitis acuteHepatobiliary disorders2/150/71/1330/68
Abdominal painGastrointestinal disorders1/150/73/1332/68
Enterocolitis haemorrhagicGastrointestinal disorders1/150/70/1330/68
Most frequent other events
Showing 10 of 122
Most frequent other events
EventChild-Pugh Class AChild-Pugh Class BAxitinibPlacebo
FatigueGeneral disorders12/152/746/13318/68
Decreased appetiteMetabolism and nutrition disorders6/155/762/13314/68
DiarrhoeaGastrointestinal disorders9/151/771/1338/68
HypertensionVascular disorders7/153/772/1339/68
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders8/152/745/1334/68
NauseaGastrointestinal disorders5/153/735/1337/68
Weight decreasedInvestigations5/153/736/1332/68
HyponatraemiaMetabolism and nutrition disorders1/153/78/1333/68
DysphoniaRespiratory, thoracic and mediastinal disorders6/153/733/1330/68
Abdominal painGastrointestinal disorders6/151/745/13312/68

Baseline characteristics

Full analysis set (FAS) included all randomized participants, and participants were classified according to the randomized treatment arm regardless of what treatment, if any, was received.

Age, Customized
Age, Customized(Participants)Child-Pugh Class AChild-Pugh Class BAxitinibPlaceboTotal
<18 years00000
18-44 years407415
45-64 years557432116
>=65 years62533293
Sex: Female, Male
Sex: Female, Male(Participants)Child-Pugh Class AChild-Pugh Class BAxitinibPlaceboTotal
Female32241241
Male12511056183
08

Study locations

77 sites
  • Alta Bates Summit Comprehensive Cancer Center
    Berkeley, California 94704, United States
  • UCSD Medical Center- La Jolla
    La Jolla, California 92037, United States
  • Moores UCSD Cancer Center
    La Jolla, California 92093, United States
  • University of California Irvine Medical Center
    Orange, California 92868, United States
  • UCSD Medical Center- Hillcrest
    San Diego, California 92103, United States
  • Florida Hospital Transplant Center, Liver Unit
    Orlando, Florida 32804, United States
  • Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 86169, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89119, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Penn Presbyterian Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • CHC Clinique Saint-Joseph
    Liège, 4000, Belgium
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
  • Guangdong General Hospital
    Guangzhou, Guangdong 510080, China
  • Nanjing Bayi Hospital
    Nan Jing, Jiangsu 210002, China
  • Jiang Su Cancer Hospital
    Nanjing, Jiangsu 210009, China
  • Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University
    Hangzhou, Zhejiang 310016, China
  • The PLA 307 Hospital
    Beijing, 100071, China
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
  • Centre Hospitalier Universitaire d'Amiens
    Amiens, 80054, France
  • Hopital Saint André
    Bordeaux Cedex, 33075, France
  • CHU Cote de Nacre
    Caen, cedex 05, 14033, France
  • Bichat-Beaujon Service Inter Hospitalier De Cancerologie
    Clichy, 92118, France
  • Hopital De La Croix-Rousse
    Lyon Cedex 04, 69317, France
  • UPCET-CIC Timone
    Marseille, 13005, France
  • CHRU Montpellier-Hopital Saint Eloi - Departement Oncologie Medicale
    Montpellier Cedex 05, 34295, France
  • Hôpital L'Archet Ii
    Nice, 06200, France
  • Hôpital Saint Antoine
    Paris, 75012, France
  • Centre Eugène Marquis
    Rennes, 35042, France
  • CHRU de Purpan.
    Toulouse Cedex, 31059, France
  • Medizinische Klinik mit Schwerpunkt
    Berlin, 13353, Germany
  • Universitätsklinikum Bonn
    Bonn, 53105, Germany
  • Klinikum der Ludwig-Maximilians-Universitaet , Campus Grosshadern
    München, 81377, Germany
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Prince of Wales Hospital
    Shatin, N.T., Hong Kong
  • Semmelweis Egyetem I.sz. Belgyógyászati Klinika
    Budapest, 1083, Hungary
  • Szegedi Tudományegyetem Onkoterápiás Klinika
    Szeged, 6720, Hungary
  • Istituto di Ematologia ed Oncologia Medica, Lorenzo ed Ariosto Seragnoli,
    Bologna, 40138, Italy
  • Policlinico S.Orsola-Malpighi Dipartimento di Ematologia e Scienze Oncologiche "L. E A. Seragnoli"
    Bologna, 40138, Italy
  • Ospedale Versilia,Oncologia Medica
    Lido Di Camaiore (LU), 55043, Italy
  • Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori IRST
    Meldola (FC), 47014, Italy
  • Unita Operativa Oncologia Medica IRCCS Fondazione Salvatore Maugeri
    Pavia, 27100, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • Unità Operativa Oncologica Medica
    Roma, 00168, Italy
  • Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria aile Scotte
    Siena, 53100, Italy
  • Aichi Cancer Center Central Hospital, Diagnostic and Interventional Radiology
    Nagoya, Aichi 464-8681, Japan
  • Chiba University Hospital
    Chiba City, Chiba 260-0858, Japan
  • Gifu Municipal Hospital
    Gifu-shi, Gifu 5008513, Japan
  • Kanazawa University Hospital
    Kanazawa, Ishikawa 920-8641, Japan
  • Kinki University Hospital
    Osaka-Sayama, Osaka 589-8511, Japan
  • Shizuoka Cancer Center
    Suntou-gun, Shizuoka 411-8777, Japan
  • Sasaki Foundation Kyoundo Hospital
    Chiyoda-Ku, Tokyo 1010062, Japan
  • Nihon University Itabashi Hospital
    Itabashi-Ku, Tokyo 173-8610, Japan
  • Yamanashi Prefectural Central Hospital
    Kofu-Shi, 400-8506, Japan
  • National Cancer Center/ Center for Liver Cancer
    Goyang-si, 410-769, Korea, Republic of
  • Samsung Medical Center, Division of Hematology-Oncology, Department of Medicine
    Seoul, 135-710, Korea, Republic of
  • Asan Medical Center, Division of Oncology, Department of Internal Medicine
    Seoul, 138-736, Korea, Republic of
  • Fakultna nemocnica s poliklinikou F. D. Roosevelta Banska Bystrica
    Banska Bystrica, 975 17, Slovakia
  • Narodny onkologicky ustav
    Bratislava, 833 10, Slovakia
  • POKO Poprad s.r.o.
    Poprad, 058 01, Slovakia
  • Nemocnica Poprad, a.s.
    Poprad, 058 45, Slovakia
  • Changhua Christian Hospital
    Changhua, 500, Taiwan
  • Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung, 833, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • Chi-Mei Medical Center LiouYing
    Tainan, 736, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Chang Gung Medical Foundation Linkou Branch
    Taoyuan, 333, Taiwan
  • The Christie NHS Foundation Trust
    Withington, Manchester M20 9BX, United Kingdom
  • Clatterbridge Centre for Oncology NHS Foundation Trust
    Liverpool, L6 7BA, United Kingdom
  • Royal Liverpool and Broadgreen University Hospital
    Liverpool, L69 3GA, United Kingdom
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
  • Hammersmith Hospital
    London, W12 OHS, United Kingdom
09

References and documents

Publications

  • Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin S, Kim RD, Casey M, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, Kudo M. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol. 2015 Dec;26(12):2457-63. doi: 10.1093/annonc/mdv388. Epub 2015 Sep 18. PubMed 26386123 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2010 to primary completion in Mar 2014, 38 months.

Results were first posted in May 2015, 1 year 2 months after primary completion. A results delay was requested in Mar 2014.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 38 months is close to that.

Counting every sponsor, half of 428 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2010
First posted
Sep 28, 2010
StartActual
Dec 6, 2010
Primary completionActual
Mar 3, 2014
CompletionActual
Dec 20, 2016
Results delay requested
Mar 4, 2014
Results first posted
May 27, 2015
Last update
Jan 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01210495
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 28, 2010
Start date
Dec 6, 2010
Primary completion
Mar 3, 2014
Completion
Dec 20, 2016
Results posted
May 27, 2015
Last update
Jan 9, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion